---
title: "AIM ImmunoTech completes Phase 2 DURIPANC trial enrollment for Ampligen-Imfinzi in metastatic pancreatic cancer"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290694603.md"
description: "AIM ImmunoTech has completed enrollment in the Phase 2 DURIPANC trial, evaluating Ampligen combined with AstraZeneca’s Imfinzi for metastatic pancreatic cancer. Interim results were positive, showing encouraging clinical observations without significant toxicity. Primary endpoint analysis begins December 2026, with topline results expected Q1 2027. Secondary assessments follow in June 2027, aiming to guide Phase 3 planning and potential pivotal registration studies."
datetime: "2026-06-24T12:29:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290694603.md)
  - [en](https://longbridge.com/en/news/290694603.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290694603.md)
---

# AIM ImmunoTech completes Phase 2 DURIPANC trial enrollment for Ampligen-Imfinzi in metastatic pancreatic cancer

-   AIM ImmunoTech completed enrollment in the Phase 2 DURIPANC trial testing Ampligen with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. \* Interim results have already been presented as positive, citing encouraging clinical observations with no significant toxicity reported. \* The primary endpoint analysis is scheduled to begin in December 2026, with topline results expected in Q1 2027. \* Secondary assessments, including progression-free survival and overall survival, are expected to start in June 2027. \* The readouts are positioned to guide Phase 3 planning and a potential registration-focused pivotal study. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606240829PRIMZONEFULLFEED9751376) on June 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)

## Related News & Research

- [REG - AstraZeneca PLC - Update on eVOLVE-Lung02 Phase III trial](https://longbridge.com/en/news/296062318.md)
- [AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies](https://longbridge.com/en/news/296114723.md)
- [AstraZeneca halts lung cancer trial of volrustomig in latest blow to pipeline](https://longbridge.com/en/news/296069146.md)
- [AstraZeneca: Tagrisso Plus Orpathys Phase III Trial Shows PFS, OS Improvements In EGFRm Lung Cancer](https://longbridge.com/en/news/296071807.md)
- [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md)